🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

We announced new icotrokinra (JNJ-2113) data from a subgroup analysis of the ICONIC-LEAD study in moderate-to-severe plaque psoriasis (PsO), presented at the 2025 World Congress of Pediatric Dermatology (#WCPD) Annual Meeting. Learn more in our latest press release:

We are excited to welcome Greg Vosganian, MD, as our Vice President of Clinical Development! Greg brings over 13 years of experience in hematology and oncology drug development to Protagonist. He has led phase 1 through phase 3 clinical development programs evaluating small

We appreciated the opportunity to connect with medical experts alongside our partners from Takeda at the 2025 MPN-MDS US Focus Meeting in Austin! This year’s theme, “Updating Knowledge & Clinical Practice in 2025,” sparked thoughtful discussions on how evolving MPN-MDS

We are very pleased to share that an abstract featuring results from VERIFY, a Phase 3 study of rusfertide, was accepted for presentation at the Plenary Session at #ASCO2025. Read more: bit.ly/4lIXhZV

.Fast Company's annual list of the World's Most Innovative Companies spotlights organizations across various industries that are driving meaningful change through groundbreaking ideas and transformative technologies. Protagonist is honored to have been recognized as a Most

Today at FiercePharma Engage, Dinesh V. Patel, PhD Dinesh V. Patel will share how Protagonist has translated cutting-edge science into successful late-stage candidates with a strategy of partnering at key inflection points. Looking forward to it!

Today, we reported financial results for the first quarter 2025 and provided a corporate update. See the full press release here: bit.ly/4iJfYtD

Pleased to share new data from #SID2025: Icotrokinra (oral IL-23R antagonist) showed 66% scalp and 77% genital clearance at Week 16 in Phase 3 ICONIC-TOTAL. We also presented preclinical data on PN-881, our next-gen oral IL-17 antagonist. 🔗 bit.ly/4kfMTr9

Today on #ClinicalTrialsDay, we give our sincere thanks to all the dedicated individuals making an impact in clinical research! At Protagonist, we are especially grateful for the progress made in our hematology and I&I programs as a result of the collective effort of everyone

Join us this Sunday, June 1st at 2:09PM CDT as Dr. Andrew Kuykendall (Andrew Kuykendall MD) from Moffitt Cancer Center presents an abstract featuring results from the VERIFY Phase 3 study in patients with polycythemia vera (PV) during the Plenary Session at #ASCO25. More details here:

Results from the Phase 3 VERIFY trial of rusfertide are being featured in today's #ASCO25 Plenary Session, presented by Dr. Andrew T. Andrew Kuykendall MD of Moffitt Cancer Center (Moffitt Cancer Center). ASCO’s selection of the VERIFY trial for plenary presentation is an important milestone

Live from #ASCO25: Moffitt’s Andrew Kuykendall, MD, (Andrew Kuykendall MD) presents practice changing results from the VERIFY study, sharing that rusfertide significantly improves outcomes for patients with polycythemia vera. Key takeaways: • Phase 3 VERIFY study compared the hepcidin

Live from #ASCO25: Andrew Kuykendall, MD, (Andrew Kuykendall MD) joins us to share the practice changing results from the VERIFY study that he presented at the ASCO Plenary Session. Key takeaways: • Rusfertide significantly reduced the need for therapeutic phlebotomies. 77% of

After the plenary presentation yesterday at #ASCO25, Dinesh V. Patel, PhD Dinesh V. Patel, PhD, had a great conversation with Brad Loncar on BiotechTV about the latest rusfertide data and what's next for Protagonist.

This Wednesday at 1:25PM ET, our Dinesh V. Patel, PhD Dinesh V. Patel, PhD, will participate in a fireside chat and one-on-one meetings at #JefferiesHealthcare.   Access the webcast: feeds.issuerdirect.com/news-release.h…

Great to be back at the Jefferies Healthcare Conference. Dinesh V. Patel, PhD Dinesh V. Patel shared why our rusfertide data was called “practice-changing” by independent experts at #ASCO25, as well as what’s next for our IL-23/IL-17 programs and capital strategy. Watch the replay:

What a week for Protagonist! From the #ASCO2025 plenary spotlight on rusfertide to our investor call and #JefferiesHealthcare appearance, it’s a testament to progress and momentum ahead. Grateful to our team, partners, investigators & patients.

Great coverage of rusfertide in today’s The Wall Street Journal. Developing rusfertide has been a long, passionate journey for Protagonist Therapeutics. Thanks to team Protagonist for their tireless dedication, and to @Takeda for their excellent partnership.   wsj.com/health/healthc…